The collaboration could revolutionize healthcare by enhancing early cancer detection, improving patient outcomes, and reducing health disparities.
Microsoft has formed a partnership with Bristol Myers Squibb to accelerate early detection of lung cancer using AI-powered radiology tools, according to a Tuesday announcement.
Lung cancer ranks as the second most common cancer in both men and women, and it is the leading cause of cancer deaths in the US, according to the American Cancer Society (ACS).
The ACS estimates there will be over 229,000 new lung cancer diagnoses in 2026, with nearly 125,000 deaths.
As part of the partnership, hospitals using Microsoft’s Precision Imaging Network will be able to leverage FDA-cleared AI tools to automatically analyze medical images, detect lung disease, and hard-to-see nodules.
This supports radiologists in their workflow and can potentially identify patients with lung cancer at earlier stages for timely care.
“By combining Microsoft’s highly scalable radiology solutions with BMS’ deep expertise in oncology and drug delivery, we’ve envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies,” said Dr. Alexandra Goncalves, VP and Head of Digital Health at Bristol Myers Squibb.
The partnership focuses on improving early detection in underserved areas, reaching rural hospitals and community clinics.
“This new Microsoft collaboration reflects our commitment to breaking down barriers and addressing healthcare challenges,” said Andrew Whitehead, VP and Head of Population Health at Bristol Myers Squibb. “By deploying this solution and bringing advanced AI tools to the front lines, together we will help to address health disparities in lung cancer.”
